$91.64
+0.24%LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Outstanding operational efficiency. The company generates substantial profit from core operations.
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
LMAT โข NASDAQ
| LeMaitre Vascular, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
249.6M | 219.9M | 193.5M | 161.7M | 154.4M | 129.4M | 117.2M | 105.6M | 100.9M | 89.2M | 78.4M | 71.1M | 64.5M | 56.7M | 57.7M | 56.1M | 50.9M | 48.7M | 41.4M | 34.6M | |
GROSS PROFIT | ||||||||||||||||||||
(71.1M) | (69M) | (66.4M) | (56.8M) | (53M) | (44.7M) | (37.4M) | (31.6M) | (30.2M) | (26.2M) | (24.2M) | (22.7M) | (19.4M) | (15.9M) | (17.5M) | (14.3M) | (13.6M) | (14.8M) | (10.7M) | (9.4M) | |
178.5M | 150.9M | 127M | 104.9M | 101.4M | 84.6M | 79.9M | 73.9M | 70.7M | 62.9M | 54.2M | 48.4M | 45.1M | 40.9M | 40.2M | 41.7M | 37.3M | 33.9M | 30.7M | 25.3M | |
OPERATING INCOME | ||||||||||||||||||||
(110.6M) | (98.6M) | (90.3M) | (78.1M) | (65M) | (55.8M) | (58.7M) | (53.2M) | (49.6M) | (46.6M) | (43M) | (41.3M) | (40.6M) | (36.9M) | (35M) | (35.4M) | (33.5M) | (35.1M) | (33.6M) | (25.7M) | |
(96.5M) | (83M) | (72.9M) | (61.7M) | (53.2M) | (46.2M) | (49.4M) | (45M) | (43M) | (40.5M) | (36.8M) | (36M) | (34.7M) | (31.8M) | (30.6M) | (29.9M) | (27.6M) | (29.8M) | (29M) | (22.3M) | |
(14.1M) | (15.7M) | (17M) | (13.3M) | (11.8M) | (10.1M) | (9.3M) | (8.2M) | (6.6M) | (6.1M) | (5.5M) | (4.7M) | (5.2M) | (5.1M) | (4.4M) | (5.5M) | (5.9M) | (5.3M) | (4.6M) | (3.3M) | |
67.9M | 52.3M | 36.7M | 26.8M | 36.4M | 28.8M | 21.2M | 28.2M | 21.1M | 16.3M | 11.5M | 6.3M | 4.5M | 4.2M | 3.7M | 4M | 1.9M | -2.9M | -4.3M | -679K | |
PRE-TAX INCOME | ||||||||||||||||||||
(5.2M) | (205K) | (0.0) | (0.0) | (2.2M) | (1.3M) | (0.0) | (2K) | (21K) | (14K) | (0.0) | (5K) | (12K) | (1K) | (0.0) | (5K) | (26K) | (61K) | (0.0) | (0.0) | |
7.9M | 4.7M | 3.1M | 986K | -2M | -1.1M | 698K | 629K | 158K | 67K | 13K | -4K | -8K | 77K | 11K | 26K | 12K | 469K | 0.0 | 0.0 | |
(0.0) | (0.0) | (485K) | (3.1M) | (0.0) | -470K | (0.0) | (235K) | (3K) | -94K | -89K | -4K | -182K | -324K | (0.0) | (0.0) | (0.0) | (0.0) | (7K) | (94K) | |
7.3M | 4.6M | 2.8M | 661K | -2.1M | -1.4M | 496K | 235K | 3K | -94K | -89K | -20K | -190K | -247K | 62K | 10K | 266K | 109K | 1.6M | 159K | |
75.2M | 56.9M | 39.5M | 27.5M | 34.3M | 27.4M | 21.7M | 28.4M | 21.1M | 16.2M | 11.4M | 6.3M | 4.3M | 4M | 3.8M | 4M | 2.2M | -2.8M | -2.7M | -520K | |
NET INCOME | ||||||||||||||||||||
(17.5M) | (12.8M) | (9.4M) | (6.9M) | (7.4M) | (6.1M) | (3.7M) | (5.5M) | (3.9M) | (5.7M) | (3.7M) | (2.4M) | (1.1M) | (1.4M) | (1.6M) | -2M | (617K) | (493K) | (232K) | (652K) | |
57.7M | 44M | 30.1M | 20.6M | 26.9M | 21.2M | 17.9M | 22.9M | 17.2M | 10.6M | 7.8M | 3.9M | 3.2M | 2.6M | 2.1M | 6M | 1.6M | -3.3M | -2.9M | -1.2M |
LMAT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 14, 2026 | April 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 14, 2026 | April 08, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 07, 2025 | September 30, 2025 | 2025 | |
8-K/A 8-K/A 2025 (Amended) N/A | November 07, 2025 | June 02, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 06, 2025 | June 30, 2025 | 2025 |
Continue your LMAT research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.